ABUS vs JPM · P/E 5.4, rev $6.2M vs P/E 14, rev $182.45B
Arbutus Biopharma Corp (ABUS) versus JPMorgan Chase & Co (JPM) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
JPMorgan Chase & Co (JPM) is a banks - diversified company listed on US. It is led by Jamie Dimon.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported JPM revenue for 2025-12-31 was $182.45B. Net income was $57.05B. Revenue was up 2.8% from 2024-12-31 to 2025-12-31. JPM currently screens at market cap $805.69B and trailing P/E 14.2.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. JPM currently screens at market cap $805.69B and trailing P/E 14.2.
Not investment advice. Open the ABUS and JPM stock pages for the full models.
Not investment advice.